 So, thanks for making time for this presentation. Actually, is the audio on? Audio is okay. So, I am going to introduce Vinedi and this is very early what the company's all about But we are in Armenia also, so I'm going to talk about why Armenia? Why Vinedi chose to come to Armenia beyond besides just me being Armenia There was actually more to it, which we're going to talk to it. So, but I'm going to talk about What problem are we solving? Why software is important? Why Armenia became important for Vinedi? So, first is as Aram said This first of all what Vinedi is it is a software company focused on commercializing New wave of Drugs that they're coming to market that is called precision medicine Which means what precision medicine means is Love the drugs today like pills that people buy for a some kind of disease is made at the batch of 10,000 or hundreds of thousands for specific disease like Penicillin or aspirin or many forms of other products New generation of therapies, which are pharmaceutical products is called precision medicine Which means they're learning how to make a drug that is tied to specific make-up of a individual and Love the almost like 40% of the next generation of pharmaceutical products are really precision made that means the Therapy is tied to the patient Where they're seeing a tremendous result in this is what's known as a CAR T therapy CAR T is your part of your white blood cells That they're learning how to extract that from the say a leukemia patient Engineer that blood cells To fight the cancer and they've learned to do this with leukemia cancer initially as a matter of fact last week FDA, which is the regulatory body in the US gave the Commercial license to Novartis to sell this in a for leukemia patients in the US, which is going to expand it to Europe But what we're seeing is This precision medicine as you can see it's a curative result. It's not just delays the cancer. It's actually with leukemia skin cancer They're seeing a 50 to 70 up to 80 percent curative result. So What sort of led to this what sort of this Precision medicine sort of was been happening the last 20 30 years We sort of seeing a sort of a major influence, but Everybody knows about DNA sequencing. That sort of was the foundation of we learn about how to be that encode humans DNA We learn from that how to do gene editing how to modify whether it's a Abnormal gene or modify the gene to be able to react to disease this led to Immuno oncology and stem cell. What's immuno oncology? Immuno oncology uses your immune system You modify your white blood cells to fight that disease back when you have a cancer Usually your immune system does not fight the cancer and they really learn from these two technologies how to modify the cells in your immune system to fight the the cancer and Really what led this is this one patient in 2012 her name is Emily Whitehead At University of Pennsylvania that they have sort of learned By since she applying gene editing. She was a leukemia patient. She was Young she was gonna die at 2012 they sort of Essentially, she was one of the first cases that actually use the this CAR T therapy to sort of cure her Leukemia in 2012. So this sort of what led to commercialization of the first wave of the precision medicine type 2 Immuno oncology But it what is this is doing is sort of creating a whole category of pharmaceuticals Whole category of companies that initially they blood cancer or leukemia is where they starting this Therapies, but then the next wave is solid tumor Next wave is the hereditary diseases because it all goes back into gene editing They're learning how to model modify your genes to sort of fix either the deficiencies or be able to fight the disease back Again, it is a big market because I set up to 40% of the next wave of pharmaceutical is going to be tied to this kind of therapies Now the question is That's the science. Okay, so our company when Eddie We're not a therapy company. We sort of build a software stack for this next wave of therapeutics that they're focused in this Space the question is why software important? So love the Novartis of the world or the big or small biotechs of the world They're sort of doing this discuss the drug discovery But what they want to do is sell curative therapies at the large scale So what's missing in this new precision medicine is there is a technology gap to be able to Make this therapy, which is what happened to Emily but make it available to a broader patient population The question is why does software matter? So let me Skip this. This is what we do. We do a platform that makes this curative effect scale in the large Patient population, but let me sort of describe to you how gene editing works so gene editing starts with a raw product from the patient blood or A DNA sequence from a solid tumor You send that result to a Company like Novartis, which they sort of have a manufacturing facility for gene editing tied to specific disease like leukemia or melanoma or others They sort of re-engineered the cells tied to one patient the final product, which is what gets Produced as a product that is designed for rosmix leukemia Get shipped back to the patient at say Stanford Medical Center to be infused to the patient Notice this cycle is Different than the pill pill is manufactured inside a manufacturing four walls and that's where pharmaceuticals Responsibility lies this model The the drugs Safety the drugs Patient safety the drugs compliance that the regulators care it starts with point of care Doing this right because I have to extract that blood from rosmix Body at Stanford Medical Center These two steps happen in Novartis gene editing the final step goes back into Patient at Stanford so the cycle that the patient interacts with that precision medicine Starts from the hospital to pharma back to the hospital. So what's missing is to do that is a software system That can manage Ordering scheduling blood collection at the hospital to transportation to manufacturing to back to the patient So you sort of have to guarantee this cycle end-to-end is safe Assisted with the patient and there's critical things coming to play called chain of identity chain of custody Which means how do you guarantee? That rosmix product goes back to rosmix How do you guarantee that you do not give that to the wrong patient because if you give the wrong product the wrong patient It's a kill How do you guarantee as you go through this workflow this life cycle? You're not making a mistake that the system is reproducible at the commercial scale at the not at the volume of Emily for one person at the low scale But at the volume of thousands or tens of thousands of patients at the higher volume you have to guarantee This thing is operating correctly correctly. So this is what Venedy does we build a software system that sort of Streamlines this entire process from the ordering scheduling collection, but they're tied to a specific therapies for Novartis for Genetic for a slew of companies. There's up to 800 clinical trials happening in this space And there's gonna be a broad category of products coming to market from leukemia to melanoma to Sickle cell disease and so on and so on so so you know the thing is to do this software Notice the software for how many of your computer science people in this room. So This software has to live in the cloud The only way you could do this because remember some of these components are at the hospital Some of these components are at the Novartis biotech manufacturing But you have to guarantee this entire flow is happening correctly The only way that's possible is to do that in the cloud in a safe secure and extremely Compliant manner. This is what Venedy sells to companies and it's really designed for any biotech company That is sort of doing their commercial studies. They're about to commercialize. They're about to go to FDA They need to have a system like these to be able to sell at the larger scale. So again last week if Novartis got the approval to sell the But if you read the fine line, it says they can only sell they can only Deal with 300 patients a year for next year. The reason is two-fold One is it's a new product to market Second one is they don't have this digital pipeline in production yet for them to get to a next wave of customers Which is more like thousands of patients. They need a system like this into place again, as I said What Venedy is it is a software. It's a software system. We built from scratch that actually manages at the entire chain and So that's what we do But the company as I said the reason why I got interested in this company one is that in my previous company Documenting we were actually also going after pharmaceutical. So at first design I have a lot of insight in pharma space We were also looking at how to manage the clinical trial documentation for big pharma This sort of takes it to the next level. It's actually closer to drug discovery drug development pipeline It's actually this is sort of the sort of the workflow that actually delivers the product electronically from point-of-care all the way to Manufacturing it's also tied to patient safety. It ties to streamlining the entire Collection and the supply chain logistics. So it sort of has a a lot more meaningful insight and it's also New wave of therapy that is going to revolutionize the way pharmaceutical deals with Very acute diseases where there's cancer hereditary at large But it's a software software system in the cloud It needs to be designed to work with a nurses hospital staff. It needs to work with pharmaceutical Manufacturing people at the Novartis of the word So it's a very mission critical software if this system is down say for ten minutes for bugs or other reason It costs the Novartis tens of millions. So it's a very sizable system So and it does have big investors behind it. This is not kind of a software that you could go in the garage Build it and sell it to Novartis. First of all Novartis would want a company that has sizable investment behind it so Because all of our customers are mid-sized to large-sized buy buy biotech or pharma companies and Remember this company wants into production These therapies are there for long number of years as a matter of fact our software not only is digitizing the product flow Product delivery flow. It's also going to be involved with the patient monitoring after treatment So which means once the system goes into place for the next ten twenty years. It has to be You know operating so it's not something you use and next year you forget it sort of a production system for a For a long time to come. That's why it's something like this requires not only a kick-ass team software developers designers product managers, but requires a very agile Organization and then I said we originally started the company in Silicon Valley But my management team my board was asking me hey Rosmic when you're gonna extend the team outside Silicon Valley because We need to grow and also our customer base is in US and where is half of the Biotech company in the world in Europe, right? They're either in Basel Switzerland France Germany Israel and all of those countries so half of our customer base. They're gonna be in US Other half is gonna be in Europe. So we We started saying okay. They asked asked me, you know Rosmic Let's extend the company to traditional places India China Hungary said okay. How about Armenia? This is why Armenia said are they developers in Armenia said yes, so I had to tell a story to our Our board members, which is this is GE venture Draper Fisher Jefferson, which is the investor behind Tesla So they said tell me about Armenia. We have no idea what Armenia We know about Armenian wine and cognac, but we know about some of the other people So I had to educate which some of you know about this the stats behind the Armenian IT And then I had to talk about some of the other good stuff, which you know the cognac the shoe and Other effect and then I had to go and talk about you know all of this other stuff that everybody knows about but really led to The Conan in Armenia, which the other person that it's important in Venedi. I hired nurses O'Hanian who leads our product development for and Nurses and Conan met so there was a personal connection love the our board members new Conan and this picture was important But it led into two years ago in when I was here We sort of had an event called create together So create together was a forum where a lot of the Silicon Valley high-tech people from Armenian descent came here to Yerevan and we were trying to sort of collaborate and Essentially create new things in our mini era one So if you notice in this picture, Rosmik is there nurses is there and actually our product designer Eric was also there, too And actually what's more important is the last day of the event Here's Rosmik here's nurses and who is in the middle is Digran, which is gonna speak to so Digran leads Venedi Arminio and he's sort of our anchor person that sort of Core core person we hired first in February of this year and around Digran We build a team and gonna talk about where we want to go and why Venedi Arminio is important to Venedi at large It's not about only the engineers We also have want to have the balanced team by saying balance team we need we mean designers product managers And the software engineers like the team that would cover the entire flow and also the QA Yeah, right. So another good point another Important thing I want to highlight here is what we call here follow the Sun You may know that we are 12 hour difference Against San Francisco or against Los Angeles, Tamsung. So for us for some people This may seem like a disadvantage, but for us, it's like it's an advantage because we cover 24-hour days if any of our customers will call us will feel there is somebody to pick up the phone and Either it will be from Arminio or from San Francisco team So we have 24-hour coverage there And also you may notice that With these plans we are planning to grow 100% year over year. So 10 people This year 20 plus people next year It's a bit aggressive plans, but I think we can Accomplish that The next important thing I want to talk about is The product line that we have you may notice this slide that Rasmik presented This is the flow that we are going through and the product line we are covering I'm extremely excited to say that one of the products from this flow was designed here from the scratch So with this team here with five people here We were able to design and develop a product from scratch that meets all the Healthcare regulations and HIPAA compliance of US market. That's that's a huge thing for me And now at the end I want to say In this presentation, we have a single ask The ask is we are hiring now and if you have any good developers designers pms or any qa people Feel free to refer us because we have this aggressive growth plan and we need to Make sure that we are done with that. So thank you. Thank you for coming. That's it